CHOU2 PHARMA - Key Persons

Job Titles:

• Chief Executive Officer
• Chief Marketing Officer

Job Titles:

• Board Director & Chair of Audit and Compensation
• Compassion - First Pet Hospitals As Executive Vice President and Chief Financial Officer
• PHARMA With Expert

Alison Cornell provides CHOU2 PHARMA with expert guidance on fundraising, use of funds, risk management, internal controls, distribution, while navigating a high growth market. Ms. Cornell is an accomplished and highly skilled global senior executive, business leader and strategist. Her extensive board of director interactions and significant executive leadership accomplishments cover categories including animal health, healthcare, chemicals, consumer products and telecommunications industries. In July 2017, Ms. Cornell joined Compassion-First Pet Hospitals as executive vice president and chief financial officer, responsible for all aspects of financial management, capital allocation, acquisition due diligence and integration, risk management, clinical trials, Informatics, purchasing, facilities and OSHA. She played a lead role in recapitalizing the company, which resulted in the highest EBITDA multiple and valuation achieved in the industry to date. Previous to her work at Compassion-First, Ms. Cornell held the position of executive vice president and chief financial officer at International Flavors & Fragrances (NYSE:IFF), and corporate senior vice president and chief financial officer at Covance Inc., a global drug development company located in more than 60 countries with and annual revenue of $2.5B and more than 12,500 employees, as well as several substantial leadership roles at AT&T over the course of 19 years, including leading finance for a $30 billion division, as vice president, forecasting, performance and investment analysis.

Dr. Casta has more than seven years of experience in treating, educating and advocating for patients in both her primary care sports-medicine practice and the medical cannabis arena. She's also the team physician for the USA Judo and USA Ski teams. While pursuing her subspecialty in Sports Medicine in Massachusetts, Dr. Casta learned about the use of medical cannabis as a treatment option for various medical conditions. This experience led her to four years with Cannacare, a major New England-based company, where she provided services to patients who qualified for medical cannabis treatments for various conditions. She was an asset in the implementation and treatment care for medical cannabis in the states of Maine and Massachusetts. Dr. Casta has joined Mr. Wilcox, Mr. Jones and Mr. Smith in their efforts to standardize cannabis as a medical pathway, leveraging education on the endocannabinoid system and dosing-on which Dr. Casta is considered an expert.

Job Titles:

• Chief Technical Officer

Blake Smith works closely with CHOU2 PHARMA's team of veterinarians and doctors to formulate, test and refine a science-first product line to treat every possible need state of every animal. His expertise in the all-natural isolation, extraction and encapsulation of cannabinoid molecules is fundamental to CHOU2 PHARMA's trade-secret Cannolation Purification System. His pharmaceutical and educational backgrounds aid the company's clinical trial and continuing education efforts. Mr. Smith brings over five years of experience in formulating and compounding cannabinoids for the medical cannabis industry, built on his previous career in pharmaceutical formulation and education. He's the owner and chief scientific officer of Zion Medicinals in Utah and is regarded as the state's leading cannabinoid expert. Working closely with universities and regulatory agencies, he helps innovate/compound cannabinoids for specific conditions. He earned a bachelor's degree in biology and political science from the University of Utah and a master's degree in biostatistical analysis epidemiology from Westminster College.

Dr. Eleanor Green is highly regarded within the veterinary industry and has a special interest in the future of veterinary medicine, specifically around the innovations that will help ensure a thriving profession. Her expertise contributes to the development of CHOU2 PHARMA products, clinical trials and continuing education efforts. She also plays a key role in legal advocacy efforts. Dr. Green held the Carl B. King deanship of the Texas A&M University College of Veterinary Medicine & Biomedical Sciences (CVM) and is a Diplomate of the American College of Veterinary Internal Medicine (ACVIM) and the American Board of Veterinary Practitioners (ABVP). She earned her Bachelor of Science (BS) in Animal Science from the University of Florida and a Doctor of Veterinary Medicine (DVM) from Auburn University. After establishing a veterinary practice in Mississippi as partner/owner, she became a founding faculty member of the College of Veterinary Medicine at Mississippi State University. Her prestigious academic appointments include: equine faculty member at Middlebush Equine Center at the University of Missouri, head of the Department of Large Animal Clinical Sciences and director of the Large Animal Hospital at the University of Tennessee, chair of the Department of Large Animal Clinical Sciences and the chief of staff of the large animal hospital at the University of Florida.

Job Titles:

• Advisor
• Member of the American College of Veterinary Surgeons

Dr. Sadanaga is a member of the American College of Veterinary Surgeons, the Veterinary Cancer Society, the Delaware Valley Academy, and other regional and national veterinary medical associations.

Job Titles:

• Executive Chairman
• Vice Chairman
• As Executive Chairman

As executive chairman, John Payne leads efforts to establish a nationwide presence for CHOU2 PHARMA, strategically targeting key markets that already have awareness of cannabinoid science. His background in animal health includes entering rapidly expanding new markets, driving the adoption of innovative technology, setting up international distribution and launching category-leading products. Mr. Payne also serves as vice chairman, board of directors for National Veterinary Associates (NVA) and was previously president and CEO of Compassion-First Pet Hospitals. Mr. Payne served as a member of the global leadership team for Mars Pet Care and was previously president and CEO of Banfield Pet Hospitals as well as president and general manager of Bayer Healthcare's North American Animal Health Division.

Job Titles:

• Co - Founder & Acting Business Development Officer

Joseph Wakim provides CHOU2 PHARMA with strategic expertise, multi-industry connections in all areas of the business, negotiation and contract guidance, philanthropic efforts, in addition to scale, contingency and succession planning. Mr. Wakim co-founded and served as CEO of Mid-Atlantic Veterinary Specialists, where he oversaw the group's acquisition by Compassion-First Pet Hospitals. Additionally, Mr. Wakim has extensive experience in the cannabis industry as a farm co-founder and owner. Based on a 30-year career in hospitality, Mr. Wakim's vast and varied background aids him in creating cross-industry connections and creative concepts.

Job Titles:

• Founder and CEO of Endoflor / Manufacturing Services

Lindsay Jones is at the core of CHOU2 PHARMA's manufacturing and R&D network, with a focus on scientific advancements, contingency planning, efficiency, process improvement, automation and ease of operation. He'll be critical to bringing CHOU2 PHARMA manufacturing and fulfillment in house. Mr. Jones is a senior operations professional with 40+ years of experience supporting well-known start-up businesses in the US and Canada, including Starbucks and the Original Cakerie, and has held key leadership roles with Frito Lay, Campbell's Soups and Chiquita. He was instrumental in growing the Florida Cannabis program in 2017 with the addition of five acres of cultivation space. He also expanded Curaleaf's retail footprint from one to 22 dispensaries in only 12 months, making it one of the largest in the state. His team was the first to gain approval to dispense cannabis-based medications to mobility constrained patients and veterans struggling with PTSD, accomplished through secure drive-up windows at multiple state-approved locations. In the face of exponential sales growth, he oversaw the expansion of staffing from 50 employees in 2017 to 500 by the end of 2018. Mr. Jones led the first cannabis business to achieve Global Food Safety Certification. He was an inaugural member of the National Cannabis Trade Federation and was part of the first cannabis group to address the capitol staff at the US Capitol.

Job Titles:

• Specialized Legal Counsel

Mark Cushing leads CHOU2 PHARMA's advocacy and legal efforts-working closely with his external network and Dr. Jeff Pollard-to improve the understanding, education and policy regarding cannabinoid pet health care. His focus is supporting veterinarians' ability to discuss and recommend cannabinoid-based products within their practices. Mr. Cushing provides high-level strategic advice, state and federal lobbying, regulatory and policy services and consulting to animal health and veterinary clients throughout North America. Since 2004, he has specialized in animal health, animal welfare, veterinary and veterinary educational issues, developing a cutting-edge practice across these sectors. He currently leads several industry coalitions and initiatives. Mr. Cushing has guided successful AVMA (American Veterinary Medical Association) accreditations for a growing list of veterinary colleges, including new accreditations. A frequent speaker at veterinary medicine and other animal policy conferences, he's an adjunct professor of law at the Duncan School of Law in Knoxville, Lewis & Clark Law School in Portland and the University of Oregon School of Law. He's also an honors graduate with distinction from Stanford University and the Willamette University College of Law.

Job Titles:

• Member of the Board
• Chairman of the Board of BNY Mellon Funds Trusts
• Vice Chairman of Cozen

Patrick J. O'Connor is vice chairman of Cozen O ́Connor. He is a trial lawyer who focuses his practice on litigation arising out of contracts, banking matters, estates, professional liability involving legal and accounting matters and health care. Prior to joining Cozen O ́Connor in 1973, he served as law clerk to the Hon. Thomas J. Clary, chief judge of the U.S. District Court for the Eastern District of Pennsylvania, Patrick is chairman of the board of BNY Mellon Funds Trusts, a member of the board of Crowley Chemical Company of New York City, a member of the board of PCS and Advisor Trust.

Job Titles:

• Chief Operating Officer of Curaleaf
• Co - Founder & Acting Chief

Stuart Wilcox's manufacturing contacts and experience are invaluable to CHOU2 PHARMA's launch, scale and expansion into new and international markets. His background aligns perfectly with ongoing efforts to bring operational processes in-house in a strategic, cost-effective manner. As CHOU2 PHARMA works to standardize and shape the pet cannabinoid market in a similar manner as the human cannabinoid market, Mr. Wilcox's legal and educational guidance will continue to be an asset to the company and to the industry. Mr. Wilcox brings 30 years of global supply chain and operations experience and has served on numerous cannabis and biotech innovators boards. He's currently chairman of the board for Ora Pharm, an international cannabis company based in New Zealand and partner of NuRevelation Bio-tech Company based in North Carolina. In his three years as chief operating officer of Curaleaf, Mr. Wilcox played a key role in the company's journey from a small cannabis operation in the Northeast to the world's largest cannabis company. He's been instrumental in leading all efforts to legitimize and professionalize the medical cannabis industry, including passing legislation to require SQF (Product Safety) certified programs, standard product testing and pharmaceutical and product standard operating procedures. Curaleaf has filled prescriptions for over 400,000 patients in 23 medical cannabis states.